Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

IMRX

Immuneering Corp

Dec 11 • 02:34PM ET

2.15

Dollar change -0.02
Percentage change -0.92	%

Healthcare • Biotechnology • USA • NASD

Peers: RCKT SRRK RNA SYRS STRO CUE MGTX CABA UBX ADAP

| Held by: VTI VXF CNCR IWC CHNA

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.97	Insider Own	29.18%	Shs Outstand	31.05M	Perf Week	-6.11%
Market Cap	66.76M	Forward P/E	-	EPS next Y	-1.56	Insider Trans	0.00%	Shs Float	21.99M	Perf Month	13.16%
Income	-58.07M	PEG	-	EPS next Q	-0.46	Inst Own	14.08%	Short Float	7.36%	Perf Quarter	50.35%
Sales	0.00M	P/S	-	EPS this Y	3.28%	Inst Trans	-61.36%	Short Ratio	0.29	Perf Half Y	39.61%
Book/sh	1.86	P/B	1.16	EPS next Y	13.93%	ROA	-63.66%	Short Interest	1.62M	Perf Year	-69.42%
Cash/sh	1.63	P/C	1.32	EPS next 5Y	-	ROE	-71.81%	52W Range	1.00 - 8.41	Perf YTD	-70.75%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-57.97%	ROI	-94.21%	52W High	-74.44%	Beta	-0.33
Dividend TTM	-	Quick Ratio	7.99	Sales past 5Y	-43.59%	Gross Margin	-	52W Low	115.00%	ATR (14)	0.17
Dividend Ex-Date	-	Current Ratio	7.99	EPS Y/Y TTM	-5.05%	Oper. Margin	-	RSI (14)	53.86	Volatility	8.85% 8.70%
Employees	68	Debt/Eq	0.07	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.67	Target Price	11.08
Option/Short	No / Yes	LT Debt/Eq	0.07	EPS Q/Q	-13.66%	Payout	-	Rel Volume	0.02	Prev Close	2.17
Sales Surprise	-	EPS Surprise	11.22%	Sales Q/Q	-	Earnings	Nov 13 AMC	Avg Volume	5.50M	Price	2.15
SMA20	4.52%	SMA50	2.91%	SMA200	7.50%	Trades		Volume	95,275	Change	-0.92%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-15-24	Reiterated	Needham	Buy	$20 → $15
Mar-15-24	Downgrade	TD Cowen	Outperform → Market Perform
Mar-15-24	Downgrade	Jefferies	Buy → Hold	$16 → $3
Dec-01-23	Initiated	Needham	Buy	$20
Jun-26-23	Resumed	Oppenheimer	Outperform	$25
Apr-19-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$5 → $14
Apr-19-23	Upgrade	Mizuho	Neutral → Buy	$10 → $20
Mar-30-23	Initiated	Mizuho	Neutral	$10
Feb-03-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$12 → $5
Jul-08-22	Initiated	Chardan Capital Markets	Buy	$18
Apr-01-22	Initiated	Oppenheimer	Outperform	$25
Jan-07-22	Initiated	Piper Sandler	Overweight	$41

Show Previous Ratings

Nov-27-24 08:00AM	Immuneering to Present at the Piper Sandler 36 Annual Healthcare Conference (GlobeNewswire)
Nov-13-24 04:05PM	Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -6.56% +13.45%
Oct-15-24 08:00AM	Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer (GlobeNewswire) +15.50%
Sep-13-24 08:14AM	Why Is Nanocap Immuneering Stock Trading Higher On Friday? (Benzinga) +41.26%
Sep-12-24 04:05PM	Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients (GlobeNewswire) +10.85%
08:00AM	Loading…
Aug-29-24 08:00AM	Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-06-24 04:05PM	Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -8.06%
Jul-31-24 04:05PM	Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer (GlobeNewswire) +19.47%
May-29-24 04:05PM	Immuneering to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-17-24 12:50PM	Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment (PR Newswire)
May-07-24 10:55PM	IMRX Stock Earnings: Immuneering Misses EPS for Q1 2024 (InvestorPlace) -5.45%
04:05PM	Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
May-06-24 04:30PM	Immuneering Recognizes Melanoma Awareness Month (GlobeNewswire)
Apr-09-24 12:00PM	IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models (GlobeNewswire)
Apr-03-24 04:05PM	Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
08:00AM	Loading…
Mar-27-24 08:00AM	Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations (GlobeNewswire)
Mar-18-24 11:02AM	Immuneering (IMRX) Plummets 71% in One Week: Here's Why (Zacks) +34.03%
Mar-14-24 07:00AM	Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors (GlobeNewswire) -50.68%
Mar-12-24 08:00AM	Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors (GlobeNewswire)
Mar-11-24 08:00AM	Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors (GlobeNewswire) -9.53%
Mar-06-24 08:00AM	Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning (Newsfile)
Mar-05-24 05:00PM	Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Mar-04-24 08:00AM	Immuneering to Participate in the Cowen 44th Annual Health Care Conference (GlobeNewswire)
Mar-03-24 07:01PM	Immuneering Corp (IMRX) Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com)
Mar-01-24 08:00AM	Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-20-24 08:00AM	Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer (GlobeNewswire)
Feb-14-24 03:45PM	3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave (InvestorPlace) +8.00%
Feb-01-24 08:00AM	Immuneering Announces Participation in February Investor Conferences (GlobeNewswire)
Dec-12-23 08:00AM	Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations (GlobeNewswire) -7.11%
Nov-20-23 04:05PM	Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire) +25.45%
04:05PM	Loading…
Nov-09-23 04:05PM	Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire) -11.86%
Oct-12-23 04:05PM	Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference (GlobeNewswire) -6.65%
Oct-04-23 04:05PM	Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-06-23 08:00AM	Immuneering to Present at the Morgan Stanley Healthcare Conference (GlobeNewswire)
Aug-03-23 04:05PM	Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-02-23 06:09AM	Immuneering Corporation (NASDAQ:IMRX) insiders have significant skin in the game with 28% ownership (Simply Wall St.)
Jul-05-23 09:55AM	Wall Street Analysts Think Immuneering Corporation (IMRX) Could Surge 103.8%: Read This Before Placing a Bet (Zacks)
Jun-05-23 08:00AM	Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors (GlobeNewswire)
May-30-23 08:00AM	Immuneering to Present at the Jefferies Healthcare Conference (GlobeNewswire) +6.86%
May-04-23 07:25PM	Immuneering Corporation (IMRX) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -8.75%
04:05PM	Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-18-23 09:24AM	Immuneering Announces $30 Million Underwritten Offering (GlobeNewswire) +9.60%
09:00AM	Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline (GlobeNewswire)
04:20AM	Morphic Holding, Inc. (MORF) Moves 22.5% Higher: Will This Strength Last? (Zacks)
Apr-12-23 04:05PM	Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-11-23 03:56AM	Immuneering Corporation (IMRX) Surges 18.5%: Is This an Indication of Further Gains? (Zacks) +5.78%
Apr-05-23 08:00AM	Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023 (GlobeNewswire)
Mar-28-23 08:00AM	Immuneering Appoints Harold E. Brakewood as Chief Business Officer (GlobeNewswire) -7.40%
Mar-27-23 09:55AM	Wall Street Analysts Believe Immuneering Corporation (IMRX) Could Rally 102.51%: Here's is How to Trade (Zacks)
Mar-24-23 01:25PM	Why Shares of Immuneering Jumped This Week (Motley Fool)
Mar-23-23 06:18AM	Immuneering Corporation (IMRX) Soars 16.9%: Is Further Upside Left in the Stock? (Zacks)
Mar-14-23 04:30PM	Immuneering to Present Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023 (GlobeNewswire) +5.62% -8.05%
Mar-09-23 09:55AM	Does Immuneering Corporation (IMRX) Have the Potential to Rally 210.19% as Wall Street Analysts Expect? (Zacks) +5.47%
Mar-08-23 07:14AM	Immuneering Corporation (NASDAQ:IMRX) Q4 2022 Earnings Call Transcript (Insider Monkey) +22.87%
Mar-06-23 05:45PM	Immuneering Corporation (IMRX) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +6.17%
04:05PM	Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-05-23 06:30PM	Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity (GlobeNewswire)
Feb-28-23 08:00AM	Immuneering Announces Participation in March Investor Conferences (GlobeNewswire)
Feb-27-23 08:00AM	Immuneering to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates (GlobeNewswire)
Feb-05-23 07:18AM	Immuneering Corporation (NASDAQ:IMRX) insiders, who hold 31% of the firm would be disappointed by the recent pullback (Simply Wall St.)
Jan-31-23 06:50AM	Immuneering To Present at Guggenheim 2023 Oncology Conference (GlobeNewswire)
Nov-28-22 06:50AM	Immuneering Announces First Patient Dosed in its Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations (GlobeNewswire)
Nov-16-22 06:35AM	Immuneering Third Quarter 2022 Earnings: Revenues Disappoint (Simply Wall St.)
Nov-10-22 10:15AM	Immuneering Corporation (IMRX) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
09:00AM	Immuneering Reports Third Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
09:00AM	Immuneering Presents Promising Preclinical Data on its Second Program IMM-6-415 at the 37th Annual Meeting of SITC (GlobeNewswire)
Nov-03-22 06:50AM	Immuneering Announces Participation in November Investor Conferences (GlobeNewswire) -12.80%
Oct-20-22 06:50AM	Immuneering Appoints Leah R. Neufeld as Chief People Officer (GlobeNewswire)
Oct-05-22 08:05AM	Immuneering To Present Poster on IMM-6-415 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (GlobeNewswire) -5.80%
Sep-30-22 12:00PM	What Makes Immuneering Corporation (IMRX) a New Buy Stock (Zacks) +9.15%
06:50AM	Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations (GlobeNewswire)
Sep-12-22 09:55AM	Wall Street Analysts See a 148% Upside in Immuneering Corporation (IMRX): Can the Stock Really Move This High? (Zacks) +10.82%
Sep-05-22 10:21AM	Immuneering (IMRX) Files IND for Cancer Candidate IMM-1-104 (Zacks)
Sep-02-22 08:09AM	Immuneering Announces Submission of IND Application to the FDA for Phase 1/2a Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations (GlobeNewswire) +7.05%
Aug-25-22 09:55AM	Wall Street Analysts Believe Immuneering Corporation (IMRX) Could Rally 224%: Here's is How to Trade (Zacks) -7.35%
06:50AM	Immuneering Announces Participation in September Investor Conferences (GlobeNewswire)
Aug-10-22 05:55PM	Immuneering Corporation (IMRX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Immuneering Reports Second Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-08-22 12:24PM	Immuneering (NASDAQ:IMRX) shareholders have endured a 77% loss from investing in the stock a year ago (Simply Wall St.) +11.25%
Jul-22-22 10:01AM	Lumos (LUMO) Soars 9.4%: Is Further Upside Left in the Stock? (Zacks)
Jul-11-22 07:57AM	What Type Of Shareholders Own The Most Number of Immuneering Corporation (NASDAQ:IMRX) Shares? (Simply Wall St.)
Jul-08-22 11:40AM	Why This Small-Cap Stock Is Gaining More Than 10% Today? (Benzinga) +28.85%
Jul-06-22 06:50AM	Immuneering Announces Participation in William Blair Biotech Focus Conference 2022 (GlobeNewswire) +5.80%
May-26-22 05:26PM	Immuneering Reports Data in Two Preclinical Abstracts at the ASCO 2022 Annual Meeting Highlighting Pan-KRAS/NRAS Activity of IMM-1-104 (GlobeNewswire) +11.31% +6.70%
May-20-22 06:50AM	Immuneering Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
May-10-22 06:30AM	Immuneering Reports First Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire) +13.99%
May-09-22 08:54AM	Immuneering Corporation (NASDAQ:IMRX) insiders placed bullish bets worth US$10.0m in the last 12 months (Simply Wall St.) -12.63%
May-05-22 06:50AM	Immuneering Announces Participation in Citis Biopharma VIRTUAL Co-Panel Day (GlobeNewswire) -8.36%
Apr-07-22 10:46AM	Oppenheimer Sees Gains of Over 100% in These 3 Beaten-Down Stocks (TipRanks) +5.09%
Apr-01-22 06:50AM	Immuneering Announces Participation in Piper Sandler AI/ML Investor Conference (GlobeNewswire) +14.99%
Mar-24-22 06:55AM	Immuneering Announces Participation in the 21st Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-10-22 08:46AM	Is a Surprise Coming for Immuneering (IMRX) This Earnings Season? (Zacks)
06:30AM	Immuneering Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-24-22 06:50AM	Immuneering Announces Participation in March Investor Conferences (GlobeNewswire) +5.46%
Feb-07-22 08:30AM	Should You Buy Immuneering (IMRX) Ahead of Earnings? (Zacks)
Jan-31-22 12:24PM	What Is The Ownership Structure Like For Immuneering Corporation (NASDAQ:IMRX)? (Simply Wall St.)
Jan-24-22 06:50AM	Immuneering Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Jan-19-22 08:00AM	PepGen Appoints Laurie Keating as Chair of Board of Directors (GlobeNewswire)
Jan-18-22 06:50AM	Immuneering Strengthens Board of Directors with the Appointment of Diana F. Hausman, M.D. (GlobeNewswire)
Jan-06-22 04:10PM	Immuneering Reports Compelling Preclinical Data on IMM-1-104 in NRAS Mutant Melanoma Model And Will Host Key External Expert Investor Event (GlobeNewswire) -8.66% +9.41%

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cormorant Asset Management, LP	10% Owner	Apr 01 '24	Sale	2.90	400,000	1,160,181	2,895,273	Apr 03 05:37 PM
Schall Thomas J.	Director	Mar 22 '24	Buy	2.55	2,900	7,385	2,900	Mar 25 04:03 PM
Feinberg Peter	Director	Mar 22 '24	Buy	2.55	25,000	63,713	111,766	Mar 25 09:13 AM
Brakewood Harold Eugene	Chief Business Officer	Mar 22 '24	Buy	2.57	3,900	10,015	3,900	Mar 25 09:10 AM
Morales Mallory	Chief Accounting Officer	Mar 21 '24	Buy	2.72	1,107	3,009	7,885	Mar 25 09:04 AM
Morales Mallory	Chief Accounting Officer	Mar 22 '24	Buy	2.55	393	1,000	8,278	Mar 25 09:04 AM
Neufeld Leah R	CHIEF PEOPLE OFFICER	Mar 20 '24	Buy	2.88	3,818	10,993	10,029	Mar 21 09:11 AM
Hall Brett Matthew	CHIEF SCIENTIFIC OFFICER	Mar 20 '24	Buy	2.86	7,000	20,020	345,896	Mar 21 09:06 AM
BERMAN ANN E	Director	Mar 18 '24	Buy	2.13	57,965	123,436	67,465	Mar 19 07:10 PM
Feinberg Peter	Director	Mar 18 '24	Buy	2.38	50,000	119,058	61,766	Mar 19 07:04 PM
Feinberg Peter	Director	Mar 19 '24	Buy	2.56	25,000	64,000	86,766	Mar 19 07:04 PM
Zeskind Benjamin J.	PRESIDENT AND CEO	Mar 19 '24	Buy	2.77	20,000	55,326	2,281,852	Mar 19 06:59 PM
Cormorant Asset Management, LP	10% Owner	Mar 14 '24	Sale	3.72	509,091	1,892,603	3,695,273	Mar 18 05:59 PM
Cormorant Asset Management, LP	10% Owner	Mar 15 '24	Sale	2.14	400,000	856,400	3,295,273	Mar 18 05:59 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMRX

Immuneering Corp

Upgrade your FINVIZ experience